Lipocine Inc (LPCN) 6.51 $LPCN
Nasdaq stocks posting largest volume increases
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Lipocine Inc. (LPCN) Surges: Stock Moves 11.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 8:11AM CDT
Lipocine Inc. (LPCN) was a big mover last session, as the company saw its shares rise by roughly 12% on the day.
Lipocine Announces Issuance of U.S. Patent for LPCN 1021
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent number 8,778,922, entitled "Steroidal Compositions." This patent relates to pharmaceutical compositions having testosterone undecanoate. The patent is expected to provide protection through January 2029 for LPCN 1021.
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global
Lipocine Added to Russell Microcap Index
GlobeNewswire - Mon Jun 30, 3:45PM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it was added to the Russell Microcap Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on June 27, 2014.
Lipocine to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Thu May 29, 4:18PM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 2:30 p.m. ET.
Lipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, a Novel Testosterone Ester for Oral Testosterone Replacement Therapy
GlobeNewswire - Tue May 27, 3:15PM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
Lipocine to Begin Trading on the NASDAQ Capital Market
GlobeNewswire - Tue Mar 18, 7:43AM CDT
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation that its application to list the Company's common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group. The Company's common stock is expected to begin trading on the NASDAQ Capital Market on or about March 21, 2014, under its current trading symbol "LPCN".
Lipocine to Present at the 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 26 Annual ROTH Conference on Wednesday, March 12, 2014 at 1:00 p.m. ET.
Lipocine Announces First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy
GlobeNewswire - Mon Feb 10, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Study of Oral Androgen Replacement ("SOAR"
pivotal Phase 3 clinical study. The trial is designed to evaluate the safety and efficacy of LPCN 1021, an oral testosterone replacement therapy, in hypogonadal men with low testosterone (Low T; www.lowtstudy.com). Approximately 300 patients are expected to be enrolled in multiple sites in the United States. The company expects to report top-line efficacy data for the trial in the second half of 2014 with a New Drug Application ("NDA" filing with the U.S. Food and Drug Administration (FDA) anticipated in the second half of 2015.
Lipocine to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Tue Feb 04, 9:48PM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 2014 Leerink Global Healthcare Conference on Wednesday February 12, 2014 at 10:15 a.m. EST. The conference is being held at the Waldorf Astoria in New York, NY.
Lipocine Announces New Appointments to Its Board of Directors
GlobeNewswire - Tue Jan 07, 3:00PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced changes to the Company's Board of Directors, including the appointments of Dr. Stephen Hill, Mr. Jeffrey Fink, and Dr. R. Dana Ono, and the retirements of Chairman Dr. William Higuchi and Mr. Gordhan Patel. Dr. Mahesh Patel, Lipocine President and Chief Executive Officer, has assumed the position of Chairman of the Board and Dr. Higuchi will serve as the Company's Chief Scientific Advisor.
Lipocine Chairman Receives Honorary Doctor of Science Degree From the University of Michigan
GlobeNewswire - Fri Dec 13, 3:30PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced that Dr. William I. Higuchi will receive an honorary Doctor of Science degree from the University of Michigan at the winter commencement ceremony, Sunday December 15, 2013.
Nasdaq stocks posting largest volume increases
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Lipocine Inc. (LPCN) Surges: Stock Moves 11.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 8:11AM CDT
Lipocine Inc. (LPCN) was a big mover last session, as the company saw its shares rise by roughly 12% on the day.
Lipocine Announces Issuance of U.S. Patent for LPCN 1021
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent number 8,778,922, entitled "Steroidal Compositions." This patent relates to pharmaceutical compositions having testosterone undecanoate. The patent is expected to provide protection through January 2029 for LPCN 1021.
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global
Lipocine Added to Russell Microcap Index
GlobeNewswire - Mon Jun 30, 3:45PM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it was added to the Russell Microcap Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on June 27, 2014.
Lipocine to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Thu May 29, 4:18PM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 2:30 p.m. ET.
Lipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, a Novel Testosterone Ester for Oral Testosterone Replacement Therapy
GlobeNewswire - Tue May 27, 3:15PM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
Lipocine to Begin Trading on the NASDAQ Capital Market
GlobeNewswire - Tue Mar 18, 7:43AM CDT
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation that its application to list the Company's common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group. The Company's common stock is expected to begin trading on the NASDAQ Capital Market on or about March 21, 2014, under its current trading symbol "LPCN".
Lipocine to Present at the 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 26 Annual ROTH Conference on Wednesday, March 12, 2014 at 1:00 p.m. ET.
Lipocine Announces First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy
GlobeNewswire - Mon Feb 10, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Study of Oral Androgen Replacement ("SOAR"
pivotal Phase 3 clinical study. The trial is designed to evaluate the safety and efficacy of LPCN 1021, an oral testosterone replacement therapy, in hypogonadal men with low testosterone (Low T; www.lowtstudy.com). Approximately 300 patients are expected to be enrolled in multiple sites in the United States. The company expects to report top-line efficacy data for the trial in the second half of 2014 with a New Drug Application ("NDA" filing with the U.S. Food and Drug Administration (FDA) anticipated in the second half of 2015. Lipocine to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Tue Feb 04, 9:48PM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 2014 Leerink Global Healthcare Conference on Wednesday February 12, 2014 at 10:15 a.m. EST. The conference is being held at the Waldorf Astoria in New York, NY.
Lipocine Announces New Appointments to Its Board of Directors
GlobeNewswire - Tue Jan 07, 3:00PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced changes to the Company's Board of Directors, including the appointments of Dr. Stephen Hill, Mr. Jeffrey Fink, and Dr. R. Dana Ono, and the retirements of Chairman Dr. William Higuchi and Mr. Gordhan Patel. Dr. Mahesh Patel, Lipocine President and Chief Executive Officer, has assumed the position of Chairman of the Board and Dr. Higuchi will serve as the Company's Chief Scientific Advisor.
Lipocine Chairman Receives Honorary Doctor of Science Degree From the University of Michigan
GlobeNewswire - Fri Dec 13, 3:30PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced that Dr. William I. Higuchi will receive an honorary Doctor of Science degree from the University of Michigan at the winter commencement ceremony, Sunday December 15, 2013.
